Latest News

Evobrutinib in MS – ACTRIMS Forum update


Merck KGaA announced in December the top-line results of its failed phase III trials of evobrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, but few details were available at that time. Full results have now been presented by Dr. Xavier Montalban, Barcelona, Spain, at the ACTRIMS Forum conference, held February 29-March 2 in West Palm Beach, Florida. Read More

ACTRIMS 2024 survey


Help make the NeuroSens coverage of the ACTRIMS Forum 2024 relevant to you.

Complete the survey below to tell us what topics are of greatest interest to you. Read More